# Shanghai Biotecan Pharmaceuticals Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-biotecan-pharmaceuticals-co

- Industry: Healthcare
- Headquarters: Shanghai, China
- Website: www.biotecan.com
- Latest round: Series A (May 26, 2015)
- Investors on record: 1

## About

Established in 2008 and based in Shanghai, China, Shanghai Biotecan Pharmaceuticals Co. Ltd. operates as a tumour diagnosis service provider dedicated to providing tumour detection services. It has nineteen subsidiaries. The company acquired CAP (College of American Pathologists) interlaboratory quality assessment and domestic clinical gene amplification laboratory certification (PCR laboratory certification). Biotecan has obtained 32 patents, 29 trademarks and 86 software copyrights. In May 2015, the company closed series A funding from new investor JiuYou Fund. In 2016, Shanghai Biotecan Pharmaceuticals Co. Ltd. was listed on the National Equities Exchange and Quotations. 

The company mainly provides medical services, which include individualized cancer plans, maternal and child health plans, chronic disease management, infectious disease detection, intestinal microecology. Individualized cancer solutions include genetic testing and solutions for colorectal cancer, lung cancer, breast cancer and other cancers. Shanghai Biotecan Pharmaceuticals Co. Ltd. also provides precision medicine services, which is a medical model that uses modern genetic technology, molecular imaging technology, biological information technology, combined with the patient's living environment and clinical data, to achieve accurate disease classification and diagnosis, and to develop personalized preventive treatment plans.

In 2016, the company's revenue was CNY 127.94 million, and its net income was CNY 5.47 million.

## Funding rounds

- Series A, May 26, 2015 — Jiuyou Fund

## Investors

- Jiuyou Fund (https://capitalatlas.ai/funds/jiuyou-fund) — Series A